|
[Related PubMed/MEDLINE]
Total Number of Papers: 119
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A Theoretical Analysis of the Effects of Tumor-Treating Electric Fields on Single Cells. |
--- |
| 2 |
2020 |
A Theoretical Study on the Biophysical Mechanisms by Which Tumor Treating Fields Affect Tumor Cells During Mitosis. |
DEP |
| 3 |
2020 |
An overview of potential novel mechanisms of action underlying Tumor Treating Fields-induced cancer cell death and their clinical implications. |
GBM, MPM |
| 4 |
2020 |
Barium Titanate Nanoparticles Sensitise Treatment-Resistant Breast Cancer Cells to the Antitumor Action of Tumour-Treating Fields. |
BTNPs |
| 5 |
2020 |
Combined radiotherapy and concurrent tumor treating fields (TTFields) for glioblastoma: Dosimetric consequences on non-coplanar IMRT as initial results from a phase I trial. |
CBCT, CTV, IMRT, IST/IIT, PCA |
| 6 |
2020 |
Complete radiological response following subtotal resection in three glioblastoma patients under treatment with Tumor Treating Fields. |
CR, GBM, OS, PFS, STR, TMZ |
| 7 |
2020 |
Concurrent Tumor Treating Fields (TTFields) and Radiation Therapy for Newly Diagnosed Glioblastoma: A Prospective Safety and Feasibility Study. |
AEs, ndGBM, OS, PFS, RT, TMZ |
| 8 |
2020 |
Finite element analysis of Tumor Treating Fields in a patient with posterior fossa glioblastoma. |
GTV |
| 9 |
2020 |
Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment. |
--- |
| 10 |
2020 |
Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice. |
AE, GBM, US, EMEA |
| 11 |
2020 |
Heat transfer during TTFields treatment: Influence of the uncertainty of the electric and thermal parameters on the predicted temperature distribution. |
EF |
| 12 |
2020 |
Prevention and Management of Dermatologic Adverse Events Associated With Tumor Treating Fields in Patients With Glioblastoma. |
AEs |
| 13 |
2020 |
The Practical Application of Emerging Technologies Influencing the Diagnosis and Care of Patients With Primary Brain Tumors. |
NGS |
| 14 |
2020 |
The Value of Tumor Treating Fields in Glioblastoma. |
FDA, GBM |
| 15 |
2020 |
Thermoplastic microfluidic bioreactors with integrated electrodes to study tumor treating fields on yeast cells. |
--- |
| 16 |
2020 |
Tumor Treating Fields (TTFields) Hinder Cancer Cell Motility through Regulation of Microtubule and Acting Dynamics. |
GEF-H1, RhoA, ROCK |
| 17 |
2020 |
Tumor treating fields cause replication stress and interfere with DNA replication fork maintenance: Implications for cancer therapy. |
DSBs |
| 18 |
2020 |
Tumor treating fields in neuro-oncology: integration of alternating electric fields therapy into promising treatment strategies. |
GBM |
| 19 |
2020 |
Tumor Treating Fields in the Management of Patients with Malignant Gliomas. |
GBM, MOA, ndGBM, rGBM, TMZ |
| 20 |
2020 |
Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial. |
GBM, PFS |
| 21 |
2020 |
Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. |
DCs |
| 22 |
2020 |
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. |
CTCAE, MGMT, ndGBM, OS, PFS |
| 23 |
2019 |
5-Fluorouracil as a Tumor-Treating Field-Sensitizer in Colon Cancer Therapy. |
5-FU, CRC |
| 24 |
2019 |
Alternating Electric Fields (TTFields) Activate Cav1.2 Channels in Human Glioblastoma Cells. |
--- |
| 25 |
2019 |
Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial. |
HR, LMiDD, OS, PFS |
| 26 |
2019 |
Efficacy of 150kHz tumor treating fields (TTFields) and cisplatin or pemetrexed for the treatment of mesothelioma cells in vitro. |
--- |
| 27 |
2019 |
Evaluation of the Compatibility of Electric Tumor Treating Fields with Key Anti-tumoral T-Cell Functions. |
CAR, CFSE, MOA, PB, TILs |
| 28 |
2019 |
Immunomodulatory effects of Tumor Treating Fields (TTFields) on lung cancer models. |
--- |
| 29 |
2019 |
Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. |
OS, PFS |
| 30 |
2019 |
Integration of Tumor-Treating Fields into the Multidisciplinary Management of Patients with Solid Malignancies. |
--- |
| 31 |
2019 |
Optimization of tumor treating fields using singular value decomposition and minimization of field anisotropy. |
FA, FE, GBM |
| 32 |
2019 |
Patient Reported Outcome (PRO) Among High-Grade Glioma Patients Receiving TTFields Treatment: A Two Center Observational Study. |
DSQ, HGG, PRO |
| 33 |
2019 |
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma. |
--- |
| 34 |
2019 |
The combined treatment of 150kHz Tumor Treating Fields (TTFields) and sorafenib shows In vitro and in vivo efficacy in hepatocellular carcinoma. |
--- |
| 35 |
2019 |
The dielectric properties of skin and their influence on the delivery of tumor treating fields to the torso: a study combining in vivo measurements with numerical simulations. |
SAT |
| 36 |
2019 |
Triple-drug Therapy With Bevacizumab, Irinotecan, and Temozolomide Plus Tumor Treating Fields for Recurrent Glioblastoma: A Retrospective Study. |
BEV, GBM, IRI, OS, PFS, rGBM, TMZ |
| 37 |
2019 |
Tumor treating fields and maintenance temozolomide for newly-diagnosed glioblastoma: a cost-effectiveness study. |
CR, GBM, ICER, OS, PFS, QALYs, TMZ |
| 38 |
2019 |
Tumor Treating Fields for Glioblastoma Treatment: Patient Satisfaction and Compliance With the Second-Generation Optune System. |
GBM, TMZ |
| 39 |
2019 |
Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study. |
AEs, OS, PDAC, PFS, SAEs |
| 40 |
2019 |
Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. |
--- |
| 41 |
2019 |
Tumour-treating fields (TTFields): Investigations on the mechanism of action by electromagnetic exposure of cells in telophase/cytokinesis. |
SAR |
| 42 |
2019 |
What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma? |
GBM, TMZ |
| 43 |
2019 |
[Tumor treating fields in cancer treatment in Denmark]. |
--- |
| 44 |
2019 |
[Tumor treating fields in cancer treatment in Denmark]. |
--- |
| 45 |
2018 |
A Review on Tumor-Treating Fields (TTFields): Clinical Implications Inferred From Computational Modeling. |
--- |
| 46 |
2018 |
Acceptance and compliance of TTFields treatment among high grade glioma patients. |
GBM, rHGG |
| 47 |
2018 |
Amino Acid PET Imaging of the Early Metabolic Response During Tumor-Treating Fields (TTFields) Therapy in Recurrent Glioblastoma. |
AMT |
| 48 |
2018 |
AMPK-dependent autophagy upregulation serves as a survival mechanism in response to Tumor Treating Fields (TTFields). |
AMPK, ATG7, CQ, ER, LC3-II |
| 49 |
2018 |
Direct-Current Electric Field Distribution in the Brain for Tumor Treating Field Applications: A Simulation Study. |
--- |
| 50 |
2018 |
Dose-dense temozolomide for recurrent high-grade gliomas: a single-center retrospective study. |
ddTMZ, PFS |
| 51 |
2018 |
Dosimetric Impact of a Tumor Treating Fields Device for Glioblastoma Patients Undergoing Simultaneous Radiation Therapy. |
VMAT |
| 52 |
2018 |
Dosimetric impact of tumor treating field (TTField) transducer arrays onto treatment plans for glioblastomas - a planning study. |
GBM, OAR, RT, TTField |
| 53 |
2018 |
Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition. |
EOT, GBM, SAC |
| 54 |
2018 |
Estimated lifetime survival benefit of tumor treating fields and temozolomide for newly diagnosed glioblastoma patients. |
TMZ |
| 55 |
2018 |
Estimating the Intensity and Anisotropy of Tumor Treating Fields Jsing Singular Value Decomposition. Towards a More Comprehensive Estimation of Anti-tumor Efficacy. |
FE |
| 56 |
2018 |
Functional Biological Activity of Sorafenib as a Tumor-Treating Field Sensitizer for Glioblastoma Therapy. |
ROS |
| 57 |
2018 |
Importance of electrode position for the distribution of tumor treating fields (TTFields) in a human brain. Identification of effective layouts through systematic analysis of array positions for multiple tumor locations. |
--- |
| 58 |
2018 |
Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. |
HRQoL |
| 59 |
2018 |
The Evolving Role of Tumor Treating Fields in Managing Glioblastoma: Guide for Oncologists. |
GBM, OS |
| 60 |
2018 |
Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study. |
--- |
| 61 |
2018 |
Tumor treating fields increases membrane permeability in glioblastoma cells. |
--- |
| 62 |
2018 |
Tumor Treating Fields Technology: Alternating Electric Field Therapy for the Treatment of Solid Tumors. |
--- |
| 63 |
2018 |
Tumor Treating Fields: Adjuvant Treatment for High-grade Gliomas. |
--- |
| 64 |
2018 |
Tumor-treating fields as a fourth treating modality for glioblastoma: a meta-analysis. |
CI, OR, WMD |
| 65 |
2018 |
Tumour treating fields in a combinational therapeutic approach. |
GBM |
| 66 |
2018 |
Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields: initial experience. |
FET |
| 67 |
2017 |
A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma. |
--- |
| 68 |
2017 |
Analysis of physical characteristics of Tumor Treating Fields for human glioblastoma. |
EVH, GTV, SARVH |
| 69 |
2017 |
Biological activity of tumor-treating fields in preclinical glioma models. |
TMZ |
| 70 |
2017 |
Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. |
GBM, OS, PFS, TMZ |
| 71 |
2017 |
Determining the Optimal Inhibitory Frequency for Cancerous Cells Using Tumor Treating Fields (TTFields). |
--- |
| 72 |
2017 |
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. |
--- |
| 73 |
2017 |
End-to-end workflow for finite element analysis of tumor treating fields in glioblastomas. |
FEA, MRI |
| 74 |
2017 |
Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. |
CFB, GBM, HRQoL, KPS, MMSE, TMZ |
| 75 |
2017 |
Impact of tumor position, conductivity distribution and tissue homogeneity on the distribution of tumor treating fields in a human brain: A computer modeling study. |
--- |
| 76 |
2017 |
Skin toxicities associated with tumor treating fields: case based review. |
--- |
| 77 |
2017 |
Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields. |
GBM |
| 78 |
2017 |
The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells. |
GBM, GSCs, MGMT, TMZ |
| 79 |
2017 |
Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. |
DSBs, RT |
| 80 |
2017 |
Tumor-treating fields elicit a conditional vulnerability to ionizing radiation via the downregulation of BRCA1 signaling and reduced DNA double-strand break repair capacity in non-small cell lung cancer cell lines. |
DSB, GBM, NSCLC |
| 81 |
2017 |
Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. |
OS |
| 82 |
2017 |
Tumor-Treating Fields: Nursing Implications for an Emerging Technology
. |
--- |
| 83 |
2016 |
Alternating electric fields (TTFields) in combination with paclitaxel are therapeutically effective against ovarian cancer cells in vitro and in vivo. |
--- |
| 84 |
2016 |
An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma. |
--- |
| 85 |
2016 |
An Overview of Sub-Cellular Mechanisms Involved in the Action of TTFields. |
GBM |
| 86 |
2016 |
Assessment of early response to tumor-treating fields in newly diagnosed glioblastoma using physiologic and metabolic MRI: initial experience. |
--- |
| 87 |
2016 |
Efficacy and Safety of Treating Glioblastoma With Tumor-Treating Fields Therapy. |
GBM |
| 88 |
2016 |
Electrical stimulation towards melanoma therapy via liquid metal printed electronics on skin. |
--- |
| 89 |
2016 |
First steps to creating a platform for high throughput simulation of TTFields. |
FDA, GBM |
| 90 |
2016 |
Glioblastoma: Overview of Disease and Treatment. |
GBM |
| 91 |
2016 |
Improving Tumor Treating Fields Treatment Efficacy in Patients With Glioblastoma Using Personalized Array Layouts. |
--- |
| 92 |
2016 |
Investigating an alternative ring design of transducer arrays for tumor treating fields (TTFields). |
FDA |
| 93 |
2016 |
Optune: Practical Nursing Applications. |
GBM |
| 94 |
2016 |
Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. |
MRI |
| 95 |
2016 |
Rationale and Background on Tumor-Treating Fields for Glioblastoma. |
GBM |
| 96 |
2016 |
Simplified realistic human head model for simulating Tumor Treating Fields (TTFields). |
GBM |
| 97 |
2016 |
Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series. |
GBM, OS |
| 98 |
2016 |
Tumor treating fields: a novel treatment modality and its use in brain tumors. |
GBM, OS, PFS, TMZ |
| 99 |
2016 |
Using computational phantoms to improve delivery of Tumor Treating Fields (TTFields) to patients. |
--- |
| 100 |
2015 |
An Evidence-Based Review of Alternating Electric Fields Therapy for Malignant Gliomas. |
--- |
|
A Search Service for Abbreviation / Long Form
